Latest news with #DelveDetect
Associated Press
07-05-2025
- Health
- Associated Press
New Data Show Delve Bio's Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single Test
BOSTON--(BUSINESS WIRE)--May 7, 2025-- Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data showing that its groundbreaking infectious disease test, Delve Detect, is also capable of viral subtyping for select pathogens from sequence data analyzed through its proprietary bioinformatics pipeline, Delve Decide. The data will be presented at the Pan American Society for Clinical Virology (PASCV) Annual Meeting on May 8, 2025, in Clearwater, Florida. 'Identifying a pathogen is only the first part of the story. Knowing detailed information about the virus can signal to a physician whether a patient's infection is linked to an outbreak, carries unusual risks, or requires a change in management – crucial information when treating a patient with serious infections,' said Brian O'Donovan, Ph.D., head of bioinformatics at Delve Bio. 'Our study demonstrates mNGS has the potential to provide this information as part of routine testing, eliminating the need for sequential testing and subtyping that may delay patient care.' In the study, sequencing data generated by Delve Detect were compared to a specialized database of reference genomes. The study determined viral subtypes and phylogenetic classifications delivered by the Delve Decide bioinformatics platform across a number of viruses, including St. Louis encephalitis virus, enterovirus, West Nile virus, varicella-zoster virus and HIV, and described concordance with independent testing methods. 'Metagenomics is a game-changer for diagnosing infectious diseases, delivering meaningful, detailed information about the cause of a patient's infection through a single, straightforward test,' added Steve Miller, M.D., Ph.D., chief medical officer at Delve Bio. 'This study demonstrates that Delve Detect can deliver information that can impact management based on viral subtyping information and improve patient care.' The data will be presented at the meeting in poster No. 31, Rapid, Simultaneous Viral Pathogen Detection, Subtyping and Strain Differentiation Through Unbiased Metagenomic Sequencing With Delve Detect CSF on May 8 at 2:45 p.m. The study is part of the company's overall presence at the meeting, which also includes a presentation titled Metagenomic Next Generation Sequencing for CNS Infection by Delve co-founder Charles Chiu, M.D., Ph.D., professor of laboratory medicine and medicine/infectious diseases at University of California San Francisco (UCSF) today, Wednesday, May 7, at 6 p.m. Delve Detect was built on technology developed at UCSF, which is exclusively licensed to Delve Bio. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit View source version on CONTACT: Company ContactAmy Wong Senior Director of Marketing and Business Development, Delve Bio Email:[email protected] ContactJulie McKeough 42 North for Delve Bio Email:[email protected] KEYWORD: UNITED STATES NORTH AMERICA FLORIDA MASSACHUSETTS INDUSTRY KEYWORD: AIDS HEALTH INFECTIOUS DISEASES GENETICS HEALTH TECHNOLOGY BIOTECHNOLOGY SOURCE: Delve Bio, Inc. Copyright Business Wire 2025. PUB: 05/07/2025 07:32 AM/DISC: 05/07/2025 07:31 AM
Business Wire
07-05-2025
- Health
- Business Wire
New Data Show Delve Bio's Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single Test
BOSTON--(BUSINESS WIRE)-- Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data showing that its groundbreaking infectious disease test, Delve Detect, is also capable of viral subtyping for select pathogens from sequence data analyzed through its proprietary bioinformatics pipeline, Delve Decide. The data will be presented at the Pan American Society for Clinical Virology (PASCV) Annual Meeting on May 8, 2025, in Clearwater, Florida. 'Metagenomics is a game-changer for diagnosing infectious diseases, delivering meaningful, detailed information about the cause of a patient's infection through a single test,' said Steve Miller, M.D., Ph.D., chief medical officer at Delve Bio. Share 'Identifying a pathogen is only the first part of the story. Knowing detailed information about the virus can signal to a physician whether a patient's infection is linked to an outbreak, carries unusual risks, or requires a change in management – crucial information when treating a patient with serious infections,' said Brian O'Donovan, Ph.D., head of bioinformatics at Delve Bio. 'Our study demonstrates mNGS has the potential to provide this information as part of routine testing, eliminating the need for sequential testing and subtyping that may delay patient care.' In the study, sequencing data generated by Delve Detect were compared to a specialized database of reference genomes. The study determined viral subtypes and phylogenetic classifications delivered by the Delve Decide bioinformatics platform across a number of viruses, including St. Louis encephalitis virus, enterovirus, West Nile virus, varicella-zoster virus and HIV, and described concordance with independent testing methods. 'Metagenomics is a game-changer for diagnosing infectious diseases, delivering meaningful, detailed information about the cause of a patient's infection through a single, straightforward test,' added Steve Miller, M.D., Ph.D., chief medical officer at Delve Bio. 'This study demonstrates that Delve Detect can deliver information that can impact management based on viral subtyping information and improve patient care.' The data will be presented at the meeting in poster No. 31, Rapid, Simultaneous Viral Pathogen Detection, Subtyping and Strain Differentiation Through Unbiased Metagenomic Sequencing With Delve Detect CSF on May 8 at 2:45 p.m. The study is part of the company's overall presence at the meeting, which also includes a presentation titled Metagenomic Next Generation Sequencing for CNS Infection by Delve co-founder Charles Chiu, M.D., Ph.D., professor of laboratory medicine and medicine/infectious diseases at University of California San Francisco (UCSF) today, Wednesday, May 7, at 6 p.m. Delve Detect was built on technology developed at UCSF, which is exclusively licensed to Delve Bio. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit
Associated Press
07-04-2025
- Health
- Associated Press
Delve Bio to Present on Metagenomic Next Generation Sequencing (mNGS) at the American Academy of Neurology 2025 Annual Meeting
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, will share data about its groundbreaking mNGS test, Delve Detect, at the 2025 American Academy of Neurology Annual Meeting today in San Diego. With the ability to identify more than 68,000 pathogens with a single test, Delve's mNGS technology delivers greater diagnostic yield over conventional methods of diagnosing meningitis and encephalitis. 'Diagnosing meningitis and encephalitis has historically required running test after test as physicians try to determine which pathogen is causing a patient's infection. In more than half of those cases, the cause is never found,' said Steve Miller, M.D., Ph.D., chief medical officer at Delve Bio. 'By using a metagenomic test, clinicians can detect viruses, bacteria, parasites, and fungi in just one test. It's an approach with more than seven years of real world evidence behind it showing mNGS outperforms traditional testing methods by over 20%, helping solve complex cases faster.' At this year's AAN Annual Meeting, Delve is presenting its mNGS assay and the technology behind Delve Detect. The backbone of Delve's mNGS platform is Delve Decide, which enables sequence matching of DNA and RNA to a curated database of over 68,000 pathogens through robust bioinformatic analysis, validated QC metrics, dynamic filtering, and visualization of high-quality reads; the results receive expert clinical interpretation to deliver comprehensive microbial analysis impossible through conventional testing. The strength of Delve's approach has been demonstrated through data from more than 4,800 patients tested at the University of California San Francisco (UCSF) over seven years – the largest study of its kind. The study found mNGS identified more pathogens than all other traditional methods (culture, antigen testing, PCR, and serology) combined. Published in Nature Medicine, the data showed mNGS detected pathogens in 14.4% of samples, representing 437 unique pathogen species, including DNA and RNA viruses, bacteria, fungi, and parasites. Among a subset of more than 1,000 patients treated at UCSF, 21.8% (48 of 220) of infections were identified by mNGS alone. Delve Detect is the company's flagship testing service, providing comprehensive test results with a 48-hour turnaround time after sample receipt and access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts to review results in clinical context. Delve Detect was built on technology developed at UCSF, which is exclusively licensed to Delve Bio. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit Amy Wong Senior Director of Marketing and Business Development, Delve Bio Media 42 North for Delve Bio INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES NEUROLOGY CLINICAL TRIALS RESEARCH SCIENCE SOURCE: Delve Bio, Inc. Copyright Business Wire 2025. PUB: 04/07/2025 07:27 AM/DISC: 04/07/2025 07:26 AM
